HISMAR: Intraoperative Margin Assessment Using the Histolog® Scanner to Reduce Reoperation in Breast-Conserving Surgery

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18+
SponsorHôpital du Valais

About this trial

This study evaluates whether systematic intraoperative margin assessment using the Histolog® Scanner - a confocal fluorescence microscopy device - reduces the need for reoperation after breast-conserving surgery (lumpectomy) in women with lobular carcinoma (ILC), ductal carcinoma in situ (DCIS), or invasive carcinoma with a DCIS component (NST+DCIS).

After lumpectomy, the fresh specimen is imaged in real time by the surgeon using the Histolog® Scanner, which produces histological-quality images of the specimen surface without any tissue processing. This allows immediate assessment of surgical margins in the operating room, enabling the surgeon to perform additional tissue removal if needed before closing.

Based on institutional data from 266 cases at CHVR (2021-2024), the current reoperation rate in this population is 11.3%. The study tests whether systematic use of the Histolog® Scanner in addition to standard care reduces this rate by 50% or more (to ≤5.6%). A total of 228 patients will be enrolled prospectively at the Centre Hospitalier du Valais Romand (CHVR), Sion, Switzerland. The reoperation decision is made by the multidisciplinary tumour board based on final histopathology results, independently of the intraoperative findings.

Eligibility criteria

Qualifiers

Female patient, aged 18 years or older at time of surgery.

invasive lobular carcinoma (ILC/CLI),

pure ductal carcinoma in situ (DCIS), or

invasive carcinoma of non-special type (NST) with an associated DCIS component.

Disqualifiers

Pregnancy (confirmed or suspected) at time of surgery.

Prior neo-adjuvant treatment (hormonal therapy or chemotherapy) for the current breast cancer diagnosis.

Surgical indication for mastectomy rather than BCS.

Known hypersensitivity or allergy to acriflavine (fluorescent staining agent used with the Histolog Scanner).

Trial design

Treatments tested in this trial

  • Histolog® Scanner

Treatment groups

228 Participants
are divided into 1 treatment group

Sponsors and collaborators

Hôpital du Valais

Lead sponsor

SamanTree Medical SA

Collaborator